Resonance Health Receives US FDA approval for LiverSmart
- Resonance Health (RHT) receives United States Food & Drug Administration (FDA) for its new medical device LiverSmart
- With this FDA approval, LiverSmart will be able to be marketed and sold in the US, which is the company’s largest customer base
- LiverSmart is a medical imaging analysis product and combines two existing products, FerriSmart and HepaFat-AI
- It is the fastest FDA clearance the company has achieved
- On the market, Resonance is up 36.4 per cent and trading at 15 cents
